In vivo application of beta amyloid oligomers: A simple tool to evaluate mechanisms of action and new therapeutic approaches

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2491-2505

  Balducci, Claudia ^a   Forloni, Gianluigi ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer's disease; A oligomers; Behaviour; Inflammation; Memory; Mice; Prion protein; Synaptic dysfunction; Toll like receptor 4; secretase modulators

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; GAMMA SECRETASE; MESSENGER RNA; MONOCLONAL ANTIBODY; OLIGOMER; PRION PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PRION; TOLL LIKE RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CROSSOVER PROCEDURE; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; INFORMATION PROCESSING; INNATE IMMUNITY; LONG TERM CARE; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; MEMORY DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECOGNITION; SENILE PLAQUE; SYNAPTIC TRANSMISSION; SYSTEMIC THERAPY; TASK PERFORMANCE; ALZHEIMER DISEASE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MEMORY; MOUSE; PHYSIOLOGY; PRION; PROTEIN MULTIMERIZATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENTRICULAR; LONG-TERM POTENTIATION; MEMORY; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRIONS; PROTEIN MULTIMERIZATION; TOLL-LIKE RECEPTORS;

EID: 84903699375     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990497     Document Type: Article

References (146)

1. Selkoe DJ. Folding proteins in fatal ways. Nature 2003; 426: 900-4.
2. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel abeta isoforms in Alzheimer's disease-their role in diagnosis and treatment. Curr Pharm Des. 2011; 17: 2594-602.
3. Jarrett JT, Berger EP, Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-7.
4. Levine H, 3rd. Soluble multimeric Alzheimer beta(1-40) preamyloid complexes in dilute solution. Neurobiol Aging 1995; 16: 755-64.
5. Teplow DB. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 1998; 5: 121-42.
6. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
7. Koh JY, Yang LL, Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990; 533: 315-20.
8. Katzman R. Alzheimer's disease. N Engl J Med 1986; 314: 964-73.
9. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461: 916-22.
10. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80.
11. Forloni G, Lucca E, Angeretti N, Della Torre P, Salmona M. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J Neurochem 1997; 69: 2048-54.
12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
13. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001; 24: 219-24.
14. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077-81.
15. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-6.
16. Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol 1999; 155: 23-8.
17. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4: 887-93.
18. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008; 63: 377-87.
19. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-62.
20. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999; 158: 328-37.
21. Balducci C, Tonini R, Zianni E, et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AbetaPP23 transgenic mice. J Alzheimers Dis 2010; 21: 1367-81.
22. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999; 2: 271-6.
23. Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H. Accelerated plaque accumulation, associative learning deficits, and upregulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002; 277: 22768-80.
24. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 1999; 96: 3228-33.
25. Moechars D, Dewachter I, Lorent K, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999; 274: 6483-92.
26. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20: 4050-8.
27. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22: 1858-67.
28. Wu CC, Chawla F, Games D, et al. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci U S A 2004; 101: 7141-6.
29. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-7.
30. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-7.
31. Jacobsen JS, Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2006; 103: 5161-6.
32. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain 2006; 129: 1659-73.
33. Podlisny MB, Ostaszewski BL, Squazzo SL, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995; 270: 9564-70.
34. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002; 30: 552-7.
35. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
36. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature 2002; 416: 535-9.
37. O'Hare E, Levine AS, Semotuk MT, et al. Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-d-glucose and naloxone. Behav Pharmacol 1996; 7: 742-753.
38. Richardson RL, Kim EM, Shephard RA, Gardiner T, Cleary J, O'Hare E. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res 2002; 954: 1-10.
39. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-42.
40. Klyubin I, Betts V, Welzel AT, et al. Amyloid beta protein dimercontaining human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008; 28: 4231-7.
41. Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci 2004; 24: 4535-40.
42. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004; 7: 1181-3.
43. Lowndes G, Savage G. Early detection of memory impairment in Alzheimer's disease: a neurocognitive perspective on assessment. Neuropsychol Rev 2007; 17: 193-202.
44. Yu W, Lu B. Synapses and dendritic spines as pathogenic targets in Alzheimer's disease. Neural Plast; 2012: 247150.
45. Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Annu Rev Neurosci 2008; 31: 47-67.
46. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181-93.
47. El-Agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol 2003; 2: 461-2.
48. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-91.
49. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-64.
50. Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127-9.
51. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1501-8.
52. Bertoni-Freddari C, Fattoretti P, Meier-Ruge W, Ulrich J. Computer-assisted morphometry of synaptic plasticity during aging and dementia. Pathol Res Pract 1989; 185: 799-802.
53. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 933-44.
54. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457-64.
55. Kokubo H, Kayed R, Glabe CG, Yamaguchi H. Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res 2005; 1031: 222-8.
56. Balducci C, Forloni G. APP transgenic mice: their use and limitations. Neuromolecular Med 2011; 13: 117-37.
57. Oddo S, Caccamo, A, Shepherd, JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-21.
58. Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 1999; 840: 23-35.
59. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448-53.
60. Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24: 10191-200.
61. Sheng M, Pak DT. Glutamate receptor anchoring proteins and the molecular organization of excitatory synapses. Ann N Y Acad Sci 1999; 868: 483-93.
62. Rao A, Kim E, Sheng M, Craig AM. Heterogeneity in the molecular composition of excitatory postsynaptic sites during development of hippocampal neurons in culture. J Neurosci 1998; 18: 1217-29.
63. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807.
64. Hyman BT, Van Hoesen GW, Damasio AR. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 1987; 22: 37-40.
65. Procter AW, Palmer, AM, Francis, PT, et al. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 1988; 50: 790-802.
66. Hardy J, Cowburn, R, Barton, A, et al. Region-specific loss of glutamate innervation in Alzheimer's disease. Neurosci Lett 1987; 73: 77-80.
67. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett 1988; 86: 109-13.
68. Cross AJ, Slater P, Simpson M, et al. Sodium dependent D-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases. Neurosci Lett 1987; 79: 213-7.
69. Palmer AM, Procter AW, Stratmann GC, Bowen DM. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett 1986; 66: 199-204.
70. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997; 278: 412-9.
71. Neary D, Snowden JS, Mann DM, et al. Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry 1986; 49: 229-37.
72. Aoki C, Sekino Y, Hanamura K, et al. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses. J Comp Neurol 2005; 483: 383-402.
73. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini, BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDAtype glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-75.
74. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-8.
75. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15: 349-57.
76. Podlisny MB, Walsh DM, Amarante P, et al. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 1998; 37: 3602-11.
77. Poling A, Morgan-Paisley K, Panos JJ, et al. Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. Behav Brain Res 2008; 193: 230-4.
78. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572: 477-92.
79. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000; 39: 10831-9.
80. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004; 24: 3370-8.
81. Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11: 556-61.
82. Wang J, Ikonen S, Gurevicius K, van Groen T, Tanila H. Alteration of cortical EEG in mice carrying mutated human APP transgene. Brain Res 2002; 943: 181-90.
83. Soto C, Castano EM, Kumar RA, Beavis RC, Frangione B. Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. Neurosci Lett 1995; 200: 105-8.
84. Stine WB, Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003; 278: 11612-22.
85. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28: 14537-45.
86. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988; 31: 47-59.
87. Winters BD, Bussey TJ. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. J Neurosci 2005; 25: 52-61.
88. Winters BD, Bussey TJ. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J Neurosci 2005; 25: 4243-51.
89. Huang SM, Mouri A, Kokubo H, et al. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 2006; 281: 17941-51.
90. Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007; 21: 2135-48.
91. Scholtzova H, Wadghiri YZ, Douadi M, et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer'sdisease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 2008; 86: 2784-91.
92. Zhang L, Xing Y, Ye CF, Ai HX, Wei HF, Li L. Learning-memory deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by using tetrahydroxystilbene glucoside. Behav Brain Res 2006; 173: 246-54.
93. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007; 31: 673-704.
94. Beeg M, Stravalaci M, Bastone A, Salmona M, Gobbi M. A modified protocol to prepare seed-free starting solutions of amyloid-beta (Abeta)(1)(-)(4)(0) and Abeta(1)(-)(4)(2) from the corresponding depsipeptides. Anal Biochem 2011; 411: 297-9.
95. Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc 2007; 2: 3247-56.
96. Fancy DA, Denison C, Kim K, et al. Scope, limitations and mechanistic aspects of the photo-induced cross-linking of proteins by water-soluble metal complexes. Chem Biol 2000; 7: 697-708.
97. Stravalaci M, Bastone A, Beeg M, et al. Specific recognition of biologically active amyloid-beta oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem 2012; 287: 27796-805.
98. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002; 22: 6331-5.
99. Greene JD, Baddeley AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 1996; 34: 537-51.
100. Janowsky JS, Carper RA, Kaye JA. Asymmetrical memory decline in normal aging and dementia. Neuropsychologia 1996; 34: 527-35.
101. Bird CM, Burgess N. The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci 2008; 9: 182-94.
102. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001; 36: 60-90.
103. Winters BD, Saksida LM, Bussey TJ. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 2008; 32: 1055-70.
104. Freir DB, Fedriani R, Scully D, et al. Abeta oligomers inhibit synapse remodeling necessary for memory consolidation. Neurobiol Aging 2011; 32: 2211-8.
105. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009; 106: 1971-6.
106. Verdier Y, Zarandi M, Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci 2004; 10: 229-48.
107. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 1128-32.
108. Gimbel DA, Nygaard HB, Coffey EE, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010; 30: 6367-74.
109. Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 2010; 107: 2295-300.
110. Forloni G, Balducci C. beta-amyloid oligomers and prion protein: Fatal attraction? Prion 2011; 5: 10-5.
111. Calella AM, Farinelli M, Nuvolone M, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2010; 2: 306-14.
112. Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature 2011; 466: E3-4; discussion E4-5.
113. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008; 88: 673-728.
114. Encalada SE, Moya KL, Lehmann S, Zahn R. The role of the prion protein in the molecular basis for synaptic plasticity and nervous system development. J Mol Neurosci 2008; 34: 9-15.
115. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
116. Lopez-Perez E, Zhang Y, Frank SJ, Creemers J, Seidah N, Checler F. Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10. J Neurochem 2001; 76: 1532-9.
117. Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J. Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res 2008; 5: 121-31.
118. Ghosh AK, Brindisi M, Tang J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem; 2012; 120 Suppl 1:71-83.
119. Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity 2003; 19: 781-91.
120. Stanger BZ, Datar R, Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A 2005; 102: 12443-8.
121. Wolfe MS. Gamma-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem; 2012;120 Suppl 1:89-98.
122. Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gammasecretase modulators. Nature 2008; 453: 925-9.
123. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
124. Balducci C, Mehdawy B, Mare L, et al. The gamma-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis 2011; 24: 799-816.
125. Imbimbo BP, Del Giudice E, Colavito D, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007; 323: 822-30.
126. Imbimbo BP, Giardino L, Sivilia S, et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2010; 20: 159-73.
127. Imbimbo BP, Hutter-Paier B, Villetti G, et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 2009; 156: 982-93.
128. Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of betaamyloid(1)(-)(42) secretion. J Med Chem 2005; 48: 5705-20.
129. Imbimbo BP, Frigerio E, Breda M, et al. Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects. Alzheimer Dis Assoc Disord 2012 in press
130. Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286: 2352-5.
131. Ait-ghezala G, Abdullah L, Volmar CH, et al. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. Cytokine 2008; 44: 283-7.
132. Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neurosci Lett 2009; 450: 56-9.
133. Desideri G, Cipollone F, Necozione S, et al. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role. Neurobiol Aging 2008; 29: 348-56.
134. Kopec KK, Carroll RT. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J Neurochem 1998; 71: 2123-31.
135. Weldon DT, Rogers SD, Ghilardi JR, et al. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998; 18: 2161-73.
136. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
137. Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res 2006; 83: 711-30.
138. Frank S, Copanaki E, Burbach GJ, Muller UC, Deller T. Differential regulation of toll-like receptor mRNAs in amyloid plaqueassociated brain tissue of aged APP23 transgenic mice. Neurosci Lett 2009; 453: 41-4.
139. Buchanan MM, Hutchinson M, Watkins LR, Yin H. Toll-like receptor 4 in CNS pathologies. J Neurochem 2010; 114: 13-27.
140. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006; 129: 3006-19.
141. Kakimura J, Kitamura Y, Takata K, et al. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 2002; 16: 601-3.
142. Tang SC, Lathia JD, Selvaraj PK, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 2008; 213: 114-21.
143. Walter S, Letiembre M, Liu Y, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 2007; 20: 947-56.
144. DaRocha-Souto B, Scotton TC, Coma M, et al. Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 2011; 70: 360-76.
145. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008; 60: 430-40.
146. Brouillette J, Caillierez R, Zommer N, et al. Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci 2012; 32: 7852-61.